Starpharma's new formulations demonstrate further improvement in crop protection
Starpharma today announced that its new agrochemical dendrimer formulations have shown further improved features compared to commercially available products.
The Australian: Criterion - Curing Cancer
Respected Criterion columnist for The Australian Tim Boreham reported on promising results from Starpharma’s latest studies to improve leading cancer drug docetaxel, with its proprietary dendrimer technology. He also commented on Starpharma’s very promising VivaGel portfolio.
Starpharma's docetaxel demonstrates targeted tumour delivery
Starpharma today reported significant tumour-targeting results with its proprietary dendrimer-docetaxel formulation.
VivaGel BV Phase 3 trials - recruitment complete
Starpharma today announced completion of recruitment in its two Phase 3 trials investigating VivaGel® as a treatment for bacterial vaginosis (BV).
Starpharma Signs Cancer Drug Agreement with AstraZeneca
Starpharma today announced the signing of an agreement with global pharmaceutical company AstraZeneca giving AstraZeneca the right to test certain proprietary Starpharma oncology molecules based on Starpharma’s dendrimer technology.
Herald Sun: Starpharma rates well with business columnist John Beveridge
Starpharma was featured on the back of its full year results with the well respected business commentator saying “Time to cross the fingers, keep the faith and buy.”
Starpharma Annual Report and full-year Financial Results
Starpharma today released its annual report and financial results for the year ended 30 June 2012.
Financial Results
- Cash burn (cash outflows before new capital) for the year $9.9M
- Cash position at end of year $42.8M
- A$35 million placement and share purchase plan
- Reported loss $13.7M
Shareholder update - August 2012
In this issue:
› VivaGel® BV trials on track for completion in 2012
› NDA ready – activities in place to support the BV approval submission
› Leading the way for Australian innovations
› Starpharma’s drug delivery program progresses into exciting new areas
› Crop protection agreement signed with Nufarm
› Market recognition of Starpharma
Download: Shareholder Update: August 2012 ( pdf file, 1MB)
Starpharma and Nufarm Sign Crop Protection Agreement
Nufarm Australia and Starpharma today announced the signing of an agreement under which the parties will apply Starpharma’s Priostar® dendrimer technology to develop innovative crop protection formulations for Nufarm’s product portfolio.
Appendix 4C - Quarterly Cashflow report
Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 30 June 2012.